3SBio Market Share Analysis for May 2026

三生制药集团

Health > Biotechnology and Pharmaceuticals

Domain3sbio.com

Year Founded1993

Employees5001 - 10000

Annual Revenue> $1B

3SBio

3SBio (including company regionals)

3sbio.com

See more website traffic and engagement information

3SBio Revenue up to May 2026 is > 1B

revenue generated by 3SBio top domains

3SBio top domains revenue over 3 years

Revenue for 3SBio top domains

3sbio.com> 1B

See more with Sales Intelligence

Total visits to 3SBio's top domains

Understand 3SBio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

3sbio.com31.1K

See more with Sales Intelligence

Avg. visit duration in 3SBio's top domains

Analyze 3SBio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

3sbio.com00:09:36

See more with Sales Intelligence

Avg. pageviews on 3SBio's top domains

See how 3SBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

3sbio.com4.29

See more with Sales Intelligence

3SBio top competitors by domain

Top similar sites in May 2026, ranked by their affinity

globaldata.comCompany NameGlobalDataEmployees1001 - 5000HQUnited Kingdom, LondonAnnual revenue$200M - $500MTotal visits703.1KBusiness and Consumer Services > Marketing and Advertising

Top technologies used by 3SBio

These are the website technologies, by industry, used by 3SBio top domains

Mobile (3)

Meta Viewport

Advertising (2)

PubMatic

Content Management System (1)

Joomla

Conversion & Analytics (1)

Baidu Analytics

More Technologies

3

See all

News & Signals from 3SBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

News3SBio Inc. had earnings of $200M on Apr 1st '25.In the first half of 2025, 3SBio achieved a net profit attributable to owners of approximately RMB 1.358 billion, a year-on-year increase of 24.6%; revenue of RMB 4.356 billion; gross profit of approximately RMB 3.716 billion; R&D cost of RMB 548 million, a 15% increase compared to the same period last year; and EBITDA adjusted for non-operating items of approximately RMB 1.610 billion.

News3SBio Inc. is developing cancer drug SSGJ-707.The pharmaceutical giant has inked a global agreement, excluding China, with 3SBio Inc. to develop the cancer drug SSGJ-707, underscoring its strong commitment to ongoing cancer research and innovations.

News3SBio Inc. received financing of $1.25B on May 1st '25.As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from Pfizer.